Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks

Stock Research Monitor: AGRX, COLL, and CPRX

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on AKRX sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Under assessment this morning are these four stocks: Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Agile Therapeutics

Shares in Princeton, New Jersey headquartered Agile Therapeutics Inc. saw a decline of 5.08%, ending Monday’s trading session at $0.28. The stock recorded a trading volume of 358,983 shares. The Company’s shares are trading 52.25% below their 50-day moving average. Moreover, shares of Agile Therapeutics, which focuses on the development and commercialization of prescription contraceptive products for women, have a Relative Strength Index (RSI) of 21.64.

On July 24th, 2018, Agile Therapeutics announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has affirmed the position of the Division of Bone, Reproductive and Urologic Products and denied the Company’s appeal of the December 21st, 2017 Complete Response Letter in relation to the NDA for Twirla®. The Company intends to appeal the ODEIII decision to the Office of New Drugs. Get the full research report on AGRX for free by clicking below at:

www.wallstequities.com/registration/?symbol=AGRX

Akorn

Lake Forest, Illinois headquartered Akorn Inc.’s stock rose slightly by 0.44%, closing the day at $18.31 with a total trading volume of 918,926 shares. The Company’s shares have advanced 12.40% in the past month and 26.89% in the previous three months. The stock is trading 15.46% above its 50-day moving average. Additionally, shares of Akorn, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter consumer health products, and animal health pharmaceuticals in the US and internationally, have an RSI of 63.10.

On July 25th, 2018, research firm RBC Capital Markets reiterated its ‘Sector Perform’ rating on the Company’s stock with an increase of the target price from $25 a share to $27 a share. Access the free research report on AKRX now by signing up at:

www.wallstequities.com/registration/?symbol=AKRX

Collegium Pharmaceutical

On Monday, shares in Canton, Massachusetts headquartered Collegium Pharmaceutical Inc. recorded a trading volume of 473,702 shares. The stock ended the day 0.43% lower at $18.56. The Company’s shares have advanced 48.72% over the past year. The stock is trading below its 200-day moving average by 12.39%. Furthermore, shares of Collegium Pharma, which develops and commercializes various products for patients suffering from pain, have an RSI of 35.43.

On July 10th, 2018, Collegium Pharma announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective that day. Mr. Dreyer brings over 25 years of commercial leadership and expertise in both biotechnology and pharmaceutical companies. Are you already registered with Wall St. Equities? Do so now for free, and get the report on COLL at:

www.wallstequities.com/registration/?symbol=COLL

Catalyst Pharmaceuticals

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.’s stock climbed 1.40%, finishing yesterday’s session at $2.89 with a total trading volume of 351,931 shares. The Company’s shares have advanced 3.21% in the previous three months. The stock is trading below its 200-day moving average by 10.53%. Additionally, shares of Catalyst Pharma, which focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, have an RSI of 29.13. Aspiring Member, please take a moment to register below for your free research report on CPRX at:

www.wallstequities.com/registration/?symbol=CPRX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507475